Efficacy analysis was conducted in a pooled population of 128 patients with CD30-positive MF or primary cutaneous ALCL who failed prior systemic therapies and were enrolled in the multicenter randomized phase III trial (ALCANZA) [60]. The gene discussed is TNFRSF8; the disease is anaplastic large cell lymphoma.